Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

VolitionRx Finds Simple Blood Test Detects 85% of Colorectal Cancers and Over 50% of Polyps

Published: Monday, December 02, 2013
Last Updated: Monday, December 02, 2013
Bookmark and Share
The new findings come from its ongoing prospective study with CHU Dinant Godinne | UCL Namur Hospital in Belgium.

VolitionRx Limited releases new data showing that when combining two of its proprietary NuQ® assays into one test, they can achieve  85% detection rates at  85% specificity for colorectal cancer. The data also shows that Volition’s two-assay test can detect more than 50% of precancerous polyps. 

Earlier this month, VolitionRx presented preliminary data from a 90 patient independent trial, later confirmed in a further 113 patients, at University Hospital Bonn in Germany. This data demonstrated 75% detection rates at 70% specificity when using a single NuQ assay. The Belgian team confirmed these results using the same single assay, but when combining it with another nucleosome biomarker they achieved even better results. They have now analysed 39 patients’ samples from the ongoing prospective trial which includes both healthy patients and patients with benign colon disorders. 

“This increased detection rate confirms our original hypothesis that combining nucleosomes increases the accuracy of the test,” comments Dr Jake Micallef, Chief Scientific Officer of VolitionRx.  “We hope to further increase the sensitivity and specificity by adding more biomarkers and developing a larger panel of nucleosome tests.”

Current diagnostic screening practices for colorectal cancer vary globally, from inviting at-risk groups to submit faecal occult blood tests to offering regular investigative colonoscopies. Unfortunately studies show compliance rates of between 30-60%  for faecal blood tests, likely due to the uncomfortable nature of the test.  Meanwhile, a US study found that less than 40%  of people who were offered a colonoscopy screening actually attended. 

Encouragingly, uptake of diagnostic blood tests is much higher, with one study showing annual prostate cancer screening compliance at higher than 80% . When VolitionRx’s NuQ blood test is made publically available, higher uptake could be very likely. Additionally, if the research team continue to identify at least 50% of polyps this could also have vast implications for diagnosing earlier-stage colorectal cancers.

Professor Hans Jørgen Nielsen, Professor of Surgical Oncology at Hvidovre Hospital in Denmark, recently expanded his prospective study evaluating VolitionRx’s NuQ panel as a colorectal cancer screening tool. He comments, “The 85% detection rate seen in this latest research is on par with rates achieved by faecal occult blood tests. If we could improve screening compliance by offering the public a simple, less intrusive test that is just as accurate, we could detect even more colorectal cancer cases in the earlier stages and survival rates could drastically improve.” 

This test has the potential to become a global first choice diagnostic tool, replacing faecal occult blood tests and preventing unnecessary colonoscopies around the world. The company hopes to apply for CE mark early next year and FDA approval roughly a year later.

Colorectal cancer is the third most prevalent cancer and fourth most common cause of cancer death worldwide.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

VolitionRx Invests in Laboratory Automation System
Automation will accelerate analysis of blood samples for expanded colorectal cancer screening trial.
Wednesday, August 13, 2014
VolitionRx Extends Agreement with University Hospital Bonn to Include CE Mark Performance Evaluation
The agreement also doubles the Hospital’s prospective trial of 20 cancers, and adds a range of additional vital background work.
Thursday, April 24, 2014
VolitionRx’s NuQ® Assays Demonstrate 80% Detection Rate in Prostate Cancer
Study data also demonstrates ability to distinguish between prostate and colorectal cancer.
Monday, March 17, 2014
Scientific News
NIH Researchers Identify Striking Genomic Signature for Cancer
Institute has identified striking signature shared by five types of cancer.
CRI Develops Innovative Approach for Identifying Lung Cancer
Institute has developed innovative approach for identifying processes that fuel tumor growth in lung cancer patients.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
Cancer Cells Kill Off Healthy Neighbours
Cancer cells create space to grow by killing off surrounding healthy cells, according to UK researchers working with fruit flies.
Cancer Drug Target Visualized at Atomic Resolution
New study using cryo-electron microscopy shows how potential drugs could inhibit cancer.
Genetic Mechanism Behind Cancer-Causing Mutations
Researchers at Indiana University has identified a genetic mechanism that is likely to drive mutations that can lead to cancer.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
"Gene Fusion" Drives Childhood Brain Cancers
Study co-led by Penn scientists highlights potential targets for future cancer therapies.
Enzyme Links Age-Related Inflammation, Cancer
Researchers have shown that an enzyme key to regulating gene expression -- and also an oncogene when mutated -- is critical for the expression of numerous inflammatory compounds that have been implicated in age-related increases in cancer and tissue degeneration.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!